Virology and Immunology Unit, GIGA-Infection, Immunity and Inflammation, University of Liege, Liege, Belgium.
Cellular Biology Unit, GIGA-Neurosciences, University of Liege, Liege, Belgium.
J Virol. 2018 Jul 17;92(15). doi: 10.1128/JVI.00295-18. Print 2018 Aug 1.
ORF9p (homologous to herpes simplex virus 1 [HSV-1] VP22) is a varicella-zoster virus (VZV) tegument protein essential for viral replication. Even though its precise functions are far from being fully described, a role in the secondary envelopment of the virus has long been suggested. We performed a yeast two-hybrid screen to identify cellular proteins interacting with ORF9p that might be important for this function. We found 31 ORF9p interaction partners, among which was AP1M1, the μ subunit of the adaptor protein complex 1 (AP-1). AP-1 is a heterotetramer involved in intracellular vesicle-mediated transport and regulates the shuttling of cargo proteins between endosomes and the -Golgi network via clathrin-coated vesicles. We confirmed that AP-1 interacts with ORF9p in infected cells and mapped potential interaction motifs within ORF9p. We generated VZV mutants in which each of these motifs was individually impaired and identified leucine 231 in ORF9p to be critical for the interaction with AP-1. Disrupting ORF9p binding to AP-1 by mutating leucine 231 to alanine in ORF9p strongly impaired viral growth, most likely by preventing efficient secondary envelopment of the virus. Leucine 231 is part of a dileucine motif conserved among alphaherpesviruses, and we showed that VP22 of Marek's disease virus and HSV-2 also interacts with AP-1. This indicates that the function of this interaction in secondary envelopment might be conserved as well. Herpesviruses are responsible for infections that, especially in immunocompromised patients, can lead to severe complications, including neurological symptoms and strokes. The constant emergence of viral strains resistant to classical antivirals (mainly acyclovir and its derivatives) pleads for the identification of new targets for future antiviral treatments. Cellular adaptor protein (AP) complexes have been implicated in the correct addressing of herpesvirus glycoproteins in infected cells, and the discovery that a major constituent of the varicella-zoster virus tegument interacts with AP-1 reveals a previously unsuspected role of this tegument protein. Unraveling the complex mechanisms leading to virion production will certainly be an important step in the discovery of future therapeutic targets.
ORF9p(与单纯疱疹病毒 1 [HSV-1] VP22 同源)是水痘-带状疱疹病毒(VZV)的一种包膜蛋白,对病毒复制至关重要。尽管其确切功能远未完全描述,但长期以来一直认为它在病毒的二次包膜形成中发挥作用。我们进行了酵母双杂交筛选,以鉴定与 ORF9p 相互作用的细胞蛋白,这些蛋白可能对该功能很重要。我们发现了 31 个 ORF9p 相互作用伙伴,其中包括 AP1M1,即衔接蛋白复合物 1(AP-1)的 μ 亚基。AP-1 是一种异源四聚体,参与细胞内囊泡介导的运输,并通过网格蛋白包被小泡调节货物蛋白在内体和 -高尔基网络之间的穿梭。我们证实 AP-1 在感染细胞中与 ORF9p 相互作用,并在 ORF9p 内映射潜在的相互作用基序。我们生成了 VZV 突变体,其中每个基序都单独受到损害,并确定 ORF9p 中的亮氨酸 231 对于与 AP-1 的相互作用至关重要。通过将 ORF9p 中的亮氨酸 231 突变为丙氨酸来破坏 ORF9p 与 AP-1 的结合,强烈抑制了病毒的生长,这很可能是通过阻止病毒的有效二次包膜形成来实现的。亮氨酸 231 是α疱疹病毒之间保守的二亮氨酸基序的一部分,我们表明马立克氏病病毒和单纯疱疹病毒 2 的 VP22 也与 AP-1 相互作用。这表明这种相互作用在二次包膜形成中的功能可能也是保守的。疱疹病毒会引起感染,尤其是在免疫功能低下的患者中,会导致严重的并发症,包括神经症状和中风。不断出现对抗病毒药物(主要是阿昔洛韦及其衍生物)耐药的病毒株,这迫切需要为未来的抗病毒治疗确定新的靶标。细胞衔接蛋白(AP)复合物参与了感染细胞中疱疹病毒糖蛋白的正确定位,而水痘-带状疱疹病毒包膜的主要成分与 AP-1 相互作用的发现揭示了这种包膜蛋白以前未被怀疑的作用。揭示导致病毒产生的复杂机制肯定是发现未来治疗靶标的重要一步。